Adjuvant activity of PCP-II, a polysaccharide from Poria cocos, on a whole killed rabies vaccine

Zhang, Weijiao; Cheng, Nan; Wang, Yuxia; Zheng, Xiaodong; Zhao, Yongkun; Wang, Hualei; Wang, Chong; Han, Qiuxue; Gao, Yuwei; Shan, Jing; Wang, Cuiling; Xia, Xianzhu

doi:10.1016/j.virusres.2019.06.001

Cited by 29 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rabies vaccines have been inactivated to make them completely safe (da Fontoura Budaszewski et al, 2017). However, many studies have shown that 30% of dogs failed to reach a VNA titer of 0.5 IU/ml with one dose of commercial inactivated rabies vaccine (Zhang W. et al, 2019). Modified live vaccines (MLVs) and canarypox-vectored recombinant vaccines against CDV have been applied commercially to protect carnivores for many years (Georoff, 2019).…”

Section: Discussionmentioning

confidence: 99%

“…The inactivated rabies vaccines have been applied in human and dogs for many years; however, they are expensive and need multiple inoculations to elicit effective humoral immune responses (El-Sayed, 2018). Live attenuated rabies vaccines raise safety concerns about virulence reversion and are no longer available commercially in China (Zhang W. et al, 2019). In addition, live-attenuated CDV vaccines might retain residual virulence in highly susceptible species (Rendon-Marin et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes

et al. 2020

Self Cite

View full text Add to dashboard Cite

The development of a safe and efficient multivalent vaccine has great prospects for application. Both rabies virus (RABV) and canine distemper virus (CDV) are highly infectious antigens, causing lethal diseases in domestic dogs and other carnivores worldwide. In this study, a replication-deficient human adenovirus 5 (Ad5)-vectored vaccine, rAd5-G-H, expressing RABV glycoprotein (G) and CDV hemagglutinin (H) protein was constructed. The RABV G and CDV H protein of rAd5-G-H were expressed and confirmed in infected HEK-293 cells by indirect immunofluorescence assay. The rAd5-G-H retained a homogeneous icosahedral morphology similar to rAd5-GFP under an electron microscope. A single dose of 10 8 GFU of rAd5-G-H administered to mice by intramuscular injection elicited rapid and robust neutralizing antibodies against RABV and CDV. Flow cytometry assays indicated that the dendritic cells and B cells in inguinal lymph nodes were significantly recruited in rAd5-G-H-immunized mice in comparison with the mock and rAd5-GFP groups. rAd5-G-H also activated the Th1-and Th2mediated cell immune responses against RABV and CDV in mice, which contributed to 100% survival of a lethal-dose RABV challenge without any clinical signs. In foxes, a single dose of 10 9 GFU of rAd5-G-H could elicit high levels of neutralizing antibodies against both RABV and CDV in comparison with the mock and rAd5-GFP groups. All foxes in the rAd5-GFP and mock groups died, while the foxes inoculated with rAd5-G-H all survived and showed no clinical signs of disease after being challenged with a lethal wild-type CDV strain. These results suggested that rAd5-G-H has great potential as a bivalent vaccine against rabies and canine distemper in highly susceptible dogs and wildlife animals.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The presence of VNA in serum is considered a reliable indicator, and the WHO and OIE recommend a RABV-VNA titer of ≥0.5 IU/ml as adequate to prevent RABV [ 36 , 37 ]. This standard has been applied in many reports [ 38 , 39 ]. Therefore, in this article, only RABV-VNA was detected, and RABV-T cell responses were not assessed.…”

Section: Discussionmentioning

confidence: 99%

An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens

et al. 2021

Self Cite

View full text Add to dashboard Cite

The global spread of Zika virus (ZIKV), which caused a pandemic associated with Congenital Zika Syndrome and neuropathology in newborns and adults, prompted the pursuit of a safe and effective vaccine. Here, three kinds of recombinant rabies virus (RABV) encoding the prM-E protein of ZIKV were constructed: ZI-D (prM-E), ZI-E (transmembrane domain (TM) of prM-E replaced with RABV G) and ZI-F (signal peptide and TM domain of prM-E replaced with the region of RABV G). When the TM of prM-E was replaced with the region of RABV G (termed ZI-E), it promoted ZIKV E protein localization on the cell membrane and assembly on recombinant viruses. In addition, the change in the signal peptide with RABV G (termed ZI-F) was not conducive to foreign protein expression. The immunogenicity of recombinant viruses mixed with a complex adjuvant of ISA 201 VG and poly(I:C) was tested in BALB/c mice. After immunization with ZI-E, the anti-ZIKV IgG antibody lasted for at least 10 weeks. The titers of neutralizing antibodies (NAbs) against ZIKV and RABV at week 6 were all greater than the protective titers. Moreover, ZI-E stimulated the proliferation of splenic lymphocytes and promoted the secretion of cytokines. It also promoted the production of central memory T cells (TCMs) among CD4+/CD8+ T cells and stimulated B cell activation and maturation. These results indicate that ZI-E could induce ZIKV-specific humoral and cellular immune responses, which have the potential to be developed into a promising vaccine for protection against both ZIKV and RABV infections.

show abstract

“…A polysaccharide PCP-II isolated from Poria cocos can be used as a good adjuvant for the rabies vaccine. PCP-II can enhance the level of rabies-specific humoral immunity and cellular immune response and improve the protective effect of vaccines [ 81 ].…”

Section: Antiviral Activitymentioning

confidence: 99%

“…Adjuvant for rabies vaccine [81] MARV Polysaccharide PCP-II (fucose, mannose, glucose and galactose in molar ration of 1.00:1.63:0.16:6.29)…”

Section: Poria Cocosmentioning

confidence: 99%

Medicinal Fungi with Antiviral Effect

Zhang

Ling

2022

Molecules

View full text Add to dashboard Cite

Pandemics from various viruses make natural organisms face challenges over and over again. Therefore, new antiviral drugs urgently need to be found to solve this problem. However, drug research and development is a very difficult task, and finding new antiviral compounds is desirable. A range of medicinal fungi such as Ganoderma lucidum and Cordyceps sinensis are widely used all over the world, and they can enhance human immunity and direct anti-virus activities and other aspects to play an antiviral role. Medicinal fungi are used as foods or as food supplements. In this review, the species of medicinal fungi with antiviral activity in recent decades and the mechanism of antiviral components were reviewed from the perspectives of human, animal, and plant viruses to provide a comprehensive theory based on better clinical utilization of medicinal fungi as antiviral agents.

show abstract

Adjuvant activity of PCP-II, a polysaccharide from Poria cocos, on a whole killed rabies vaccine

Cited by 29 publications

References 42 publications

A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes

A Bivalent Human Adenovirus Type 5 Vaccine Expressing the Rabies Virus Glycoprotein and Canine Distemper Virus Hemagglutinin Protein Confers Protective Immunity in Mice and Foxes

An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens

Medicinal Fungi with Antiviral Effect

Contact Info

Product

Resources

About